ArticleJournal of medical biochemistry2026
Correlation analysis of serum FGF9, Sestrin2 and HBDH with the severity of sepsis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the correlation between serum fibroblast growth factor 9(FGF9), Sestrin2 and hydroxybutyrate dehydrogenase (HBDH) and the severity of sepsis, and to analyse the predictive value of FGF9, Sestrin2 and HBDH for clinical outcome. Methods: A retrospective analysis of 125 patients with sepsis admitted to Taikang Xianlin Drum Tower Hospital and Chongqing University Central Hospital between May 2022 and May 2025 was conducted. According to disease severity, there were 50 cases in the septic shock group and 75 in the sepsis group. Based on clinical outcomes, patients were divided into a death group (103 cases) and a survival group (22 cases). Observe the levels of serum FGF9, Sestrin2 and HBDH in each group. Analysis of the relationships among FGF9, Sestrin2, HBDH, and sepsis severity was performed using the Spearman correlation coefficient. Using multivariate logistic regression analysis, the factors influencing the prognosis of patients with sepsis were investigated. FGF9, Sestrin2, and HBDH were evaluated for their prognostic utility in sepsis patients using receiver operating characteristic (ROC) curves. Results: Compared with the sepsis group, the level of FGF9 in the septic shock group was lower [(122.41± 21.45) pg/mL vs (145.36± 23.68) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(15.75± 2.34) ng/mL] vs (8.36± 0.93) ng/mL, (232.14± 34.77) U/L vs (166.25± 24.85) U/L]; the differences were statistically significant (P< 0.05). Compared with the survival group, the level of FGF9 in the death group was lower [(112.05± 20.61) pg/mL vs (133.25± 22.14) pg/mL], while the levels of Sestrin2 and HBDH were both higher [(19.25± 2.85) ng/mL] vs (12.42± 2.33) ng/mL, (261.25± 37.25) U/L vs (204.25± 32.18) U/L]. Spearman correlation coefficient analysis showed that FGF9 was negatively correlated with the severity of sepsis (P< 0.05), whereas the degree of sepsis was positively correlated with both Sestrin2 and HBDH (P< 0.05). Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation II (APACHE II), procalcitonin, FGF9, Sestrin2, and HBDH are risk factors for sepsis prognosis, according to multivariate logistic regression analysis (P< 0.05). The results of ROC curve analysis showed that the combined detection of FGF9, Sestrin2 and HBDH had a better predictive effect on the prognosis of patients with sepsis (P< 0.05). Conclusions: The amount of FGF9 in septic shock patients is comparatively low, while the levels of Sestrin2 and HBDH are relatively high. As the severity of the disease increases, the level of FGF9 gradually decreases, while the levels of Sestrin2 and HBDH gradually increase, with a certain correlation with disease severity. The prognosis of sepsis patients can be assessed by measuring FGF9, Sestrin2, and HBDH levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.